Charles Schwab
ADPT icon

Charles Schwab’s Adaptive Biotechnologies ADPT Stock Holding History

Charles Schwab’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3M Buy
1,178,552
+32,870
+3% +$504K ﹤0.01% 1695
2026
Q1 		$15.9M Sell
1,145,682
-27,853
-2% -$444K ﹤0.01% 1868
2025
Q4 		$19.1M Buy
1,173,535
+20,974
+2% +$342K ﹤0.01% 1775
2025
Q3 		$17.2M Buy
1,152,561
+110,111
+11% +$1.34M ﹤0.01% 1829
2025
Q2 		$12.1M Buy
1,042,450
+119,708
+13% +$1.09M ﹤0.01% 1915
2025
Q1 		$6.86M Sell
922,742
-33,832
-4% -$260K ﹤0.01% 2137
2024
Q4 		$5.73M Buy
956,574
+39,831
+4% +$220K ﹤0.01% 2278
2024
Q3 		$4.69M Buy
916,743
+10,262
+1% +$44.7K ﹤0.01% 2405
2024
Q2 		$3.28M Buy
906,481
+36,699
+4% +$116K ﹤0.01% 2530
2024
Q1 		$2.79M Buy
869,782
+113,850
+15% +$441K ﹤0.01% 2501
2023
Q4 		$3.7M Sell
755,932
-103,135
-12% -$471K ﹤0.01% 2429
2023
Q3 		$4.68M Buy
859,067
+21,177
+3% +$140K ﹤0.01% 2291
2023
Q2 		$5.62M Buy
837,890
+14,571
+2% +$108K ﹤0.01% 2198
2023
Q1 		$7.27M Sell
823,319
-1,080
-0.1% -$9.52K ﹤0.01% 2027
2022
Q4 		$6.3M Buy
824,399
+26,052
+3% +$203K ﹤0.01% 2093
2022
Q3 		$5.68M Sell
798,347
-295,271
-27% -$2.78M ﹤0.01% 2148
2022
Q2 		$8.85M Buy
1,093,618
+233,850
+27% +$2.06M ﹤0.01% 1906
2022
Q1 		$11.9M Buy
859,768
+19,097
+2% +$300K ﹤0.01% 1849
2021
Q4 		$23.6M Buy
840,671
+19,051
+2% +$584K 0.01% 1452
2021
Q3 		$27.9M Buy
821,620
+195,751
+31% +$7.08M 0.01% 1293
2021
Q2 		$25.6M Buy
625,869
+22,562
+4% +$877K 0.01% 1388
2021
Q1 		$24.3M Buy
603,307
+51,881
+9% +$2.81M 0.01% 1378
2020
Q4 		$32.6M Buy
551,426
+10,575
+2% +$545K 0.01% 1043
2020
Q3 		$26.3M Buy
540,851
+382,289
+241% +$16.1M 0.01% 1029
2020
Q2 		$7.67M Buy
158,562
+12,206
+8% +$445K ﹤0.01% 1799
2020
Q1 		$4.07M Buy
146,356
+54,460
+59% +$1.52M ﹤0.01% 1931
2019
Q4 		$2.75M Buy
91,896
+1,795
+2% +$51.5K ﹤0.01% 2315
2019
Q3 		$2.79M Buy
+90,101
New +$3.68M ﹤0.01% 2261

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Charles Schwab's ADPT Position: Q2 2026 in Review

Charles Schwab increased its Adaptive Biotechnologies (ADPT) stake by 2.9% in Q2 2026, buying an estimated $504K and bringing the position to 1,178,552 shares worth $25.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1695.

Charles Schwab first reported a position in ADPT in Q3 2019 and has held it in 28 quarters since. The position peaked at $32.6M in Q4 2020. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Charles Schwab held 1,178,552 shares of Adaptive Biotechnologies worth $25.3M as of Q2 2026.
  • Charles Schwab bought 32,870 Adaptive Biotechnologies shares in Q2 2026, an estimated $504K.
  • Adaptive Biotechnologies made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1695 holding.
  • Charles Schwab first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 28 quarters since.
  • Charles Schwab's Adaptive Biotechnologies position peaked at $32.6M in Q4 2020.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.